Global Car T Cell Therapy Market, by Type (Abecma, Breyanzi, Kymriah, Tecartus, and Yescarta), by Application (Cancer, Lymphoma, and Others), by End Users (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,085.0 Mn in 2021 and is expected to exhibit a CAGR of 24.5% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing in strategic development such as acquisitions, collaborations, distribution agreements, etc. which is expected to drive the growth of the global Car T cell therapy market. For instance, in July 2021, BioNTech SE biotechnology company announced the acquisition of Kite, a Gilead company. This acquisition accelerate the clinical development cell therapies in the U.S. Moreover, this acquisition would support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR (tumor neoantigen T cell receptor) program.
In addition, focus of key market players to invest in research and development is likely to fuel the growth of the market. For instance, Yescarta is a product developed by Gilead Sciences, Inc. which is in clinical trial phase 2 for oncology application.
Global Car T Cell Therapy Market– Impact of Coronavirus (COVID-19) Pandemic
The unexpected breakout of the COVID-19 pandemic has negative impact on the pharmaceutical and life sciences industries. The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. The SARS-CoV-2 coronavirus (COVID-19) pandemic is create challenges to the delivery of cellular therapy to patients with hematologic malignancies.
Browse 22 Market Data Tables and 27 Figures spread through 237 Pages and in-depth TOC on ‘Global Car T Cell Therapy Market’- Forecast to 2028, Global Car T Cell Therapy Market, by Type (Abecma, Breyanzi, Kymriah, Tecartus, and Yescarta), by Application (Cancer, Lymphoma, and Others), by End Users (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Increase in number of cases with cancer leads to increase in demand for the car T cell products and thereby drive the growth of the global cat T cell market. For instance, according to World Health Organization cancer-causing infections, such as hepatitis and human papillomavirus (HPV), are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. According to Global Cancer Statistics 2020, around 19.3 million new cancer cases and almost 10.0 million cancer deaths were recorded globally in 2020.
Key Takeaways of the Global Car T Cell Therapy Market: